Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial.
Saved in:
| Title: | Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial. |
|---|---|
| Authors: | Xiang H; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA. hong.xiang@fiveprime.com., Liu L; Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, China., Gao Y; Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, China., Ahene A; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Macal M; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; TRex Bio, Inc., South San Francisco, CA, USA., Hsu AW; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; Merck and Co., South San Francisco, CA, USA., Dreiling L; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Collins H; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Nov; Vol. 86 (5), pp. 595-606. Date of Electronic Publication: 2020 Sep 23. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 32965540 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Xiang+H%22">Xiang H</searchLink>; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA. hong.xiang@fiveprime.com.<br /><searchLink fieldCode="AU" term="%22Liu+L%22">Liu L</searchLink>; Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Gao+Y%22">Gao Y</searchLink>; Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Ahene+A%22">Ahene A</searchLink>; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA.<br /><searchLink fieldCode="AU" term="%22Macal+M%22">Macal M</searchLink>; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; TRex Bio, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hsu+AW%22">Hsu AW</searchLink>; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; Merck and Co., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Dreiling+L%22">Dreiling L</searchLink>; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA.<br /><searchLink fieldCode="AU" term="%22Collins+H%22">Collins H</searchLink>; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227806519%22">Cancer chemotherapy and pharmacology</searchLink> [Cancer Chemother Pharmacol] 2020 Nov; Vol. 86 (5), pp. 595-606. <i>Date of Electronic Publication: </i>2020 Sep 23. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>7806519 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0843 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203445704%22">03445704 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Chemother Pharmacol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32965540 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00280-020-04139-4 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 595 Titles: – TitleFull: Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Xiang H – PersonEntity: Name: NameFull: Liu L – PersonEntity: Name: NameFull: Gao Y – PersonEntity: Name: NameFull: Ahene A – PersonEntity: Name: NameFull: Macal M – PersonEntity: Name: NameFull: Hsu AW – PersonEntity: Name: NameFull: Dreiling L – PersonEntity: Name: NameFull: Collins H IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: 2020 Nov Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1432-0843 Numbering: – Type: volume Value: 86 – Type: issue Value: 5 Titles: – TitleFull: Cancer chemotherapy and pharmacology Type: main |
| ResultId | 1 |
